A comprehensive "proteogenomic" analysis of the proteins, genes, and RNA transcription involved in paediatric brain tumours has yielded a more complete understanding of these tumours, which are the leading cause of cancer-related deaths in children.
The results could help physicians more accurately identify different types of tumours and methods for treating them.
Researchers from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and Children's Brain Tumor Network (CBTN) collected and analysed what's known as genetic, genomic, and proteomic data from multiple types of brain tumours in children.
The consortia consist of collaborators from the Icahn School of Medicine at Mount Sinai, National Cancer Institute, Fred Hutchinson Cancer Research Center, Children's National Hospital, and Children's Hospital of Philadelphia.
The study, the first large-scale multicentre study focused on paediatric brain tumours, was available online in Cell.
"paediatric cancers in general, and paediatric brain tumours in particular, have a relatively low mutational burden," explains Pei Wang, PhD, lead corresponding author of the study and Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.
"Thus, comprehensive characterization of the functional molecular biology of these tumours, including the proteogenomic analysis done in this study, is essential to better understand and treat paediatric brain tumours."
This study is the first comprehensive survey of genomics (which aims to characterise DNA sequence alterations in a sample), transcriptomics (which aims to quantify copies of RNAs), global proteomics (which aims to identify and quantify proteins), and phosphoproteomics (which quantifies active proteins) across a large cohort of 218 tumour samples representing seven distinct types of brain tumours.
By characterising biological themes that are shared among these different types of tumours, the study revealed new insights suggesting that current treatments being used for specific tumour types could be applied to others that share the same proteomic features.
Specifically, the analyses revealed two distinct subgroups of paediatric craniopharyngioma, a type of paediatric brain tumour.
One subgroup showed proteomic/phosphoproteomic characteristics that were strikingly similar to those of another type of tumour, known as "low-grade glioma (LGG) with BRAFV600E mutation." This observation suggests that MEK/MAPK inhibitors, a type of chemotherapy that has been used against LGG-with-BRAFV600E-mutation tumours, might also help with this subset of paediatric craniopharyngiomas, which currently has no robust chemotherapeutic options.
"The driver of this joint study has been a commitment to data-sharing and open science.
Coming together has given both CPTAC and CBTN an opportunity to expand our available resources for answering critically important biological questions. Harnessing the collective expertise across these consortia enables us to better understand the mechanisms of paediatric tumours, improve the process of target protein identification, and potentially improve cancer treatments," said Adam Resnick, PhD, contributing researcher, Scientific Co-Chair for CBTN, and Director of the Center for Data Driven Discovery in Biomedicine (D3b) at Children's Hospital of Philadelphia.
By leveraging the rich clinical outcome data of this cohort, the research team also identified new prognostic biomarkers for a type of tumour known as high-grade glioma (HGG).
When HGG tumours have a genetic mutation known as a H3K27M mutation, they tend to be very aggressive and the patients have relatively short survival time. However, in those without the mutation, this study suggests that the abundance of proteins named IDH1 and IDH2 in the tumour tissues could help to identify which tumours with the non-mutated H3K27M gene may be less aggressive.
"Integration of the clinical, proteomic, and genetic data generated in this study allows us to construct a more comprehensive model of brain tumour biology, which will lead to more targeted treatments," said Brian Rood, MD, contributing researcher, Executive Co-Chair for CBTN, and Medical Director of the Brain Tumor Institute at Children's National Hospital.
The data analysis also showed key biological differences in samples from primary and recurrent tumours from the same patients, indicating the need for independent assessment and therapeutic decisions for these tumours.
"The current study is the first to reveal in paediatric brain tumours the power of proteins to better determine which patient might benefit from a given therapy, and our validation studies using targeted proteomics provide a platform for clinical implementation of the findings" said co-author Amanda Paulovich, MD, PhD, Aven Foundation Endowed Chair and professor in the Clinical Research Division at Fred Hutchinson Cancer Research Center.
"As this work moves further along toward clinical validation, I hope it brings comfort to patients and their families who have suffered from this terrible disease."
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.